Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764275 | 1.00 | PDE4A (0.33) | PDE4ATSHR | |
| SCHEMBL17513798 | 1.00 | PDE4A (0.33) | PDE4ATSHR | |
| SCHEMBL5029667 | 0.93 | PDE4A (0.38) | PDE4ATSHR | |
| SCHEMBL10891271 | 0.87 | PDE4A (0.30) | PDE4A | |
| SCHEMBL4761823 | 0.85 | — | — | |
| SCHEMBL511526 | 0.85 | — | — | |
| SCHEMBL3719245 | 0.85 | — | — | |
| SCHEMBL5985557 | 0.84 | PDE4A (0.34) | PDE4ATSHR | |
| SCHEMBL31168253 | 0.83 | ALDH1A1 (0.33) | PDE4ATSHR | |
| SCHEMBL3919093 | 0.82 | PDE4A (0.42) | PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273877-A1 | CAPSULE AGGREGATES | INTERNATIONAL FLAVORS AND FRAGRANCES INC. (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3197560-A1 | CAPSULE AGGREGATES | International Flavors & Fragrances Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049456-A1 | CAPSULE AGGREGATES | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| EP-2417990-A1 | Implantation compositions for use in tissue augmentation | Merz Aesthetics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-0777451-A4 | OPHTHALMIC DELIVERY SYSTEM | TEVA PHARMA (IL) | 1998-06-10 | — | — | EP | disclosed |
| EP-0777451-A1 | OPHTHALMIC DELIVERY SYSTEM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1997-06-11 | — | — | EP | disclosed |
| WO-1995035073-A1 | OPHTHALMIC DELIVERY SYSTEM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273877-A1 | CAPSULE AGGREGATES | RCC1, CAPG, CHMP4B | PDE4A 2300/4885TSHR 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.